Moneycontrol PRO
HomeNewsGepowerindia
Jump to
  • 12 stocks you should keep an eye on: Edelweiss

    Edelweiss has come out with its top picks report. Alembic Pharma, Bajaj Finance, ICICI Bank, Larsen & Toubro, Lupin, Maruti Suzuki India, Motherson Sumi Systems, Pidilite Industries, Sobha Developers, The Ramco Cements, Wipro and Zee Entertainment Enterprises are the 12 stocks in the list.

  • Buy Alembic Pharma; target of Rs 160: Firstcall Research

    Buy Alembic Pharma; target of Rs 160: Firstcall Research

    Firstcall Research is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 160 in its September 12, 2013 research report.

  • Hold Alembic Pharma; target Rs 181: Nirmal Bang

    Hold Alembic Pharma; target Rs 181: Nirmal Bang

    Brokerage house Nirmal Bang has recommended hold rating on Alembic Pharmaceuticals with a price target of Rs 181 in its August 13, 2013 research report.

  • Buy Alembic Pharma; target Rs 153: Sushil Finance

    Buy Alembic Pharma; target Rs 153: Sushil Finance

    Sushil Finance is bullish on Alembic Pharmaceuticals (APL) and has recommended buy rating on the stock with a target price of Rs 153 in its May 07, 2013 research report.

  • Buy Alembic Pharma; target Rs 119: Nirmal Bang

    Buy Alembic Pharma; target Rs 119: Nirmal Bang

    Nirmal Bang is bullish on Alembic Pharma and has recommended buy rating on the stock with a target price of Rs 119, in its March 05, 2013 research report.

  • Buy Alembic Pharma; target of Rs 95: Angel Broking

    Buy Alembic Pharma; target of Rs 95: Angel Broking

    Angel Broking is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 95 in its January 22, 2013 research report.

  • Accumulate Alembic Pharma; target of Rs 79: Sushil Finance

    Accumulate Alembic Pharma; target of Rs 79: Sushil Finance

    Sushil Finance is bullish on Alembic Pharma and has recommended accumulate rating on the stock with a target of Rs 79 in its January 23, 2013 research report.

  • Angel Broking's 12 Diwali crackers for prosperous trading

    Angel Broking's 12 Diwali crackers for prosperous trading

    The Indian equity markets are witnessing renewed confidence on positive global and domestic policy actions.

  • Buy Alembic Pharma; target of Rs 91: Angel Broking

    Buy Alembic Pharma; target of Rs 91: Angel Broking

    Angel Broking is bullish on Alembic Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 91 in its October 19, 2012 research report.

  • Buy Alembic Pharma; target of Rs 91: Angel Broking

    Buy Alembic Pharma; target of Rs 91: Angel Broking

    Angel Broking is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 91 in its August 10, 2012 research report.

  • Buy Alembic Pharma; target of Rs 86: Nirmal Bang

    Buy Alembic Pharma; target of Rs 86: Nirmal Bang

    Nirmal Bang is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 86 in its May 2, 2012 research report.

  • Buy Alembic Pharma; target of Rs 91: Angel Broking

    Buy Alembic Pharma; target of Rs 91: Angel Broking

    Angel Broking is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 91 in its April 25, 2012 research report.

  • Buy Alembic Pharma; target of Rs 82: Angel Broking

    Buy Alembic Pharma; target of Rs 82: Angel Broking

    Angel Broking is bullish on Alembic Pharma and has recommended buy rating on the stock with a target of Rs 82 in its February 10, 2012 research report.

  • Buy Alembic Pharma; target Rs 77: Angel Broking

    Buy Alembic Pharma; target Rs 77: Angel Broking

    Angel Broking is bullish on Alembic Pharma and has recommended buy rating on the stock with a target price of Rs 77 in its November 2, 2011 research report.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347